Furthermore, when BRCA2 defects are experimentally imposed upon cells in vitro or in animals, these cause PARPi sensitivity without necessarily recapitulating the mutagenic consequences of BRCA2 mutation seen in human cancers, again suggesting it is the primary HR defect that is important to PARPi sensitivity and not how defective HR moulds the genome. This evidence concerns the gene BRCA2 and cancer.